文献速递妇科

米维妥昔单抗索拉夫坦辛(靶向叶酸受体α的抗体药物偶联物)联合卡铂和贝伐珠单抗治疗铂敏感卵巢癌的1b期研究

Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2024-03-05

这项1b期研究评估了米维妥昔单抗索拉夫坦辛(MIRV)联合卡铂和贝伐珠单抗三药方案在复发性铂敏感卵巢癌患者中的抗肿瘤活性和安全性。41例参与者接受治疗,确认的客观缓解率为83%,中位缓解持续时间10.9个月,中位无进展生存期13.5个月。不良事件与各药物已知安全性一致,血小板减少是剂量调整的主要原因。

要点

  • 三药方案在复发性铂敏感FRα表达卵巢癌中确认客观缓解率达83%,中位无进展生存期13.5个月。
  • 常见不良事件为腹泻(83%)、恶心(76%)、疲乏(73%)、血小板减少(71%)和视物模糊(68%),多为轻中度。
  • 血小板减少是药物相关停药和剂量调整的主要原因。

核心结论

  • MIRV联合卡铂和贝伐珠单抗三药方案在复发性铂敏感FRα表达卵巢癌中具有高活性且不良事件可耐受。

研究设计与样本

  • 1b期研究,纳入41例复发性铂敏感上皮性卵巢癌、输卵管癌或原发性腹膜癌患者(既往1-2线治疗),接受MIRV(6 mg/kg调整理想体重)、卡铂(AUC5)和贝伐珠单抗(15 mg/kg)每3周一次。

主要发现

  • 确认的客观缓解率为83%(9例完全缓解和25例部分缓解)。
  • 中位缓解持续时间为10.9个月,中位无进展生存期为13.5个月。
  • 任何级别不良事件最常见为腹泻(83%)、恶心(76%)、疲乏(73%)、血小板减少(71%)和视物模糊(68%),多数为轻度至中度(≤2级),但血小板减少和中性粒细胞减少例外。
  • 卡铂、MIRV和贝伐珠单抗的中位周期数分别为6、12和13个周期。

关键数值与推荐

  • 入组要求叶酸受体α(FRα)免疫组化表达≥50%的细胞具有≥2+强度(PS2+评分)。
  • 卡铂可在6个周期后根据研究者判断停用;允许继续MIRV+贝伐珠单抗作为维持治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evaluate the antitumor activity and safety profile of the triplet combination of mirvetuximab soravtansine (MIRV), carboplatin, and bevacizumab in recurrent, platinum-sensitive ovarian cancer. METHODS: Participants with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer (1-2 prior lines of therapy) received MIRV (6 mg/kg adjusted ideal body weight), carboplatin (AUC5), and bevacizumab (15 mg/kg) once every 3 weeks. Carboplatin could be discontinued after 6 cycles per investigator discretion; continuation of MIRV+bevacizumab as maintenance therapy was permitted. Eligibility included folate receptor alpha (FRα) expression by immunohistochemistry (≥50% of cells with ≥2+ intensity; PS2+ scoring); prior bevacizumab was allowed. Tumor response, duration of response (DOR), progression-free survival (PFS), and adverse events (AEs) were assessed. RESULTS: Forty-one participants received triplet therapy, with a median of 6, 12, and 13 cycles of carboplatin, MIRV, and bevacizumab, respectively. The confirmed objective response rate was 83% (9 complete and 25 partial responses). The median DOR was 10.9 months; median PFS was 13.5 months. AEs (any grade) occurred as expected, based on each agent's safety profile; most common were diarrhea (83%), nausea (76%), fatigue (73%), thrombocytopenia (71%), and blurred vision (68%). Most cases were mild to moderate (grade ≤2), except for thrombocytopenia, for which most drug-related discontinuations occurred, and neutropenia. CONCLUSIONS: This triplet regimen (MIRV+carboplatin+bevacizumab) was highly active, with a tolerable AE profile in participants with recurrent, platinum-sensitive, FRα-expressing ovarian cancer. Thrombocytopenia was the primary cause of dose modifications. These outcomes compare favorably to historical data reported for platinum-based chemotherapy plus bevacizumab regimens in similar patient populations.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Richardson DL, Moore KN, Vergote I, et al. Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2024. PMID: 38447347. doi:10.1016/j.ygyno.2024.01.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。